Lung Cancer Trials Ask AI to find trials
Active Not RecruitingNot applicableNCT04056247
Official study title

Predicting Responsiveness in Oncology Patients Based on Host Response Evaluation During Anti Cancer Treatments

Study summary

The PROPHETIC study is a prospective, multi-center, international clinical study aimed at developing an algorithm to predict patient outcomes. The study involves analyzing the proteomic profiles of patients undergoing therapy to assess the likelihood of clinical benefit from their prescribed treatment. Blood samples are collected prior to and during the treatment period and analyzed as part of the ongoing development of thealgorithm.

Ask AI to explain this study
Start here

Key things to know

Main goalNot specified

This describes the study’s primary purpose.

What is being studiedPlasma sample collection

The study team can explain what participation involves.

Who it may be forNon-small cell lung cancer (NSCLC) · Small cell lung cancer (SCLC) · Early-stage or resectable

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Oct 19, 2026 · Source: ClinicalTrials.gov

Is enrollment open?Active Not Recruiting

The study is underway but is not accepting new participants.

What kind of study?Not applicable

Observational

Where is it offered?41 U.S. locations

Locations may change over time.

Who runs it?OncoHost Ltd.

Study sponsor

01
Study overview

What this study is about

Purpose
Not specified
Study type
Observational
Phase
Not applicable
Sponsor
OncoHost Ltd.
Interventions being studied
Other: Plasma sample collection
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Cancer type
Non-small cell lung cancer (NSCLC)→Small cell lung cancer (SCLC)→
Disease setting
Early-stage or resectable→Locally advanced→Metastatic or stage IV→
03
Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria
  • Provision of informed consent prior to any study-specific procedures.
  • Male or female aged at least 18 years.
  • ECOG PS - 0/1-2
  • Normal hematologic, renal and liver function: 1. Absolute neutrophil count higher than 1500/mm3 2. Platelets count higher than 100,000/mm3 3. haemoglobin higher than 9 g/dL 4. Creatinine concentration ≤1.4 mg/dL, or creatinine clearance higher than 40 mL/min 5. Total bilirubin lower than 1.5 mg/dL, ALT and AST levels ≤ 3 times above the upper normal limit.
  • At least one measurable lesion in order to enable the assessment of the response (except for stage IIIb-d malignant melanoma patients).
Reasons someone may not be able to joinExclusion criteria
  • Concurrent and/or other active malignancy that has required systemic treatment within 2 years of first dose of study drug
  • Generalized impairment or mental incompetence that would render the patient unable to understand his/her participation in the study.

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • Birmingham VAHCSBirmingham, Alabama
  • Mayo ClinicJacksonville, Florida
  • University of MiamiMiami, Florida
  • Florida Cancer Specialist and Research InstituteOrlando, Florida
  • Protean BiodiagnosicsOrlando, Florida
  • Northwest Community HealthcareRolling Meadows, Illinois
  • Helen Nassif Community Cancer CenterCedar Rapids, Iowa
  • Rutgers Cancer InstituteNew Brunswick, New Jersey
  • Roswell ParkBuffalo, New York
  • West ClinicGermantown, Tennessee
  • Michael E. Debakey VA Medical CenterHouston, Texas
  • 151-Christus Health St. MichaelTexarkana, Texas

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Oct 19, 2026. Always confirm current availability with the study team.

View original record ↗